.png)
We find out how and why drugs fail in clinical trials well before trials even start.
Find out more
A drug's journey from the bloodstream to a tumour is a long winding one.
It's a journey filled with traps, distractions, and barriers (i.e., the tumour microenvironment) all brought about by the tumour to prevent the drug from killing it.
Each tumour is different and it’s difficult to predict the strategies a tumour will use.
This is why only about 12% of solid tumour patients respond to immunotherapy.
But there's a solution.
We have built TMEmic, a next-generation in vitro model: the most accurate model of the tumour microenvironment for solid tumours.
We combine proprietary material formulations, sensors, and a comprehensive bioinformatics workflow to figure out how some cancers resist the most advanced approaches to treatment.
In doing so, we uncover ways to help drugs overcome the tumour microenvironment.
.png)
.svg){kind=small}